BioVision, the World Life Sciences Forum, Emphasises Economic Considerations in its 7th Meeting

LYON, France, December 20, 2010 /PRNewswire/ -- For its 7th meeting, BioVision (27-29 March at Lyon in France) will feature a new platform << business in science >> centred on the theme: "The end of the traditional life science industry model: what's next?"

28 international experts will be considering the future of the traditional model of the life sciences industry. Among them will be: Zhu Chen (Health Minister, China), Hatem el Gabaly (Health Minister, Egypt), Charlotte Ersb0ll (Corporate VP, Novo Nordisk), Rob ten Hoedt (President, Europe, Medtronic), Andrew Cassels (Director of strategy, WHO), Philippe Archinard (CEO, Transgene), Elias Zerhouni (President for worldwide R&D, Sanofi-aventis, Bill & Melinda Gates Foundation, and Professor at theCollege de France), John A. Thomson (VP, Strategic R&D Networks, Vertex PharmaceuticalsInc), Olivier Charmeil (Sr Vice-President Sanofi-aventis), Rajesh Parekh (Director, Head of Healthcare practice Asia, McKinsey & Company), Antonio Tajani (Vice-president, European Commission), James Geragthy (Sr Vice-President, Genzyme), Andre Choulika (Chairman, France Biotech), Anders Olauson (President, EuropeanPatients' Forum), and Michel Goldman (Executive Director, Innovative Medicine Initiative)...

"Business in science" will take the form of 4 round-table discussions on Monday 28th March:

    - How to address the growing challenge of chronic diseases in
      emerging countries?
    - How can technology innovation transform healthcare delivery?
    - How to solve R&D's challenge with Open collaborative
      Innovation?
    - Boston, Mumbai, Nairobi..? What is the geographic new deal
      for boosting innovation in infectious diseases?

This track is organised with the support of McKinsey & Company in partnership with Lyon Biopole and France Biotech.

In addition, and for the first time, a networking software tool will be provided for all registered attendees interested in organising meetings with other participants a great opportunity to make the most of their presence at BioVision.

Present at BioVision will be the main life sciences companies as well as major international companies, and biotechnology companies. They will all have the opportunity to meet and mingle with representatives from the main NGOs, with large-scale international health organisations and with governments and organisations such as the European Medicines Agency and the European Food Safety Authority.

About BioVision

For over 10 years, BioVision has been stimulating innovative, high-level debate with all the key stakeholders (industry, the political sphere, patient associations, etc.) on the societal implications of scientific progress.

Over three days, the leading decision-makers and experts in life sciences will review major scientific advances in healthcare, nutrition and the environment. They will catalyze discussion between stakeholders (who rarely have the opportunity to talk to each other) on the impact of these scientific and industrial innovations on society.

    For more information, please visit http://www.biovision.org

    Press contacts: Alize PR
    Caroline Carmagnol
    [email protected]
    Tel.: +33-(0)6-64-18-99-59

SOURCE BioVision